BGB-B167
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BGB-B167, covering 2025-05-01 to 2025-05-01. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors [Phase 1]